Chiara Lanfranchi

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis.

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis.

Journal: Clinical and translational gastroenterology

Published: January 14, 2025

Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.

Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.

Journal: Lung

Published: October 17, 2024

Lung Clearance Index Improves in People with Cystic Fibrosis not Achieving a Clinical Important Difference in Forced Expiratory Volume in One Second After Elexacaftor/Tezacaftor/Ivacaftor Therapy.

Lung Clearance Index Improves in People with Cystic Fibrosis not Achieving a Clinical Important Difference in Forced Expiratory Volume in One Second After Elexacaftor/Tezacaftor/Ivacaftor Therapy.

Journal: Lung

Published: August 06, 2024

Management of liver disease and portal hypertension in cystic fibrosis: a review.

Management of liver disease and portal hypertension in cystic fibrosis: a review.

Journal: Expert review of respiratory medicine

Published: July 04, 2024

A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators.

A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: April 21, 2024

Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis.

Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: December 13, 2023

Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.

Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.

Journal: Diabetes & metabolism

Published: January 15, 2023

Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies.

Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies.

Journal: Biomedicines

Published: July 22, 2022

Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study.

Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: March 22, 2022

Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over.

Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 19, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026